# Incyte (INCY) Financial Model

Free Excel 3-statement financial model and company analysis for Incyte.

- Canonical: https://finamodel.com/companies/incyte
- Industry: Pharmaceuticals
- Downloadable model: Yes
- Excel download: https://finamodel.com/company-models/INCY.xlsx

## Model Purpose

This model provides a comprehensive equity valuation and scenario planning tool for an equity research analyst or portfolio manager to assess Incyte's ability to offset the impending loss of exclusivity (LOE) for its blockbuster drug Jakafi through the growth of Opzelura, recent launches (Niktimvo, Zynyz), and its clinical pipeline.

## Company Overview

- Incyte Corporation is a global commercial-stage biopharmaceutical company focused on the discovery, development, and commercialisation of proprietary therapeutics, primarily in haematology, oncology, and inflammation and autoimmunity (IAI).
- **Business segments**: The company operates as a single reportable segment (Biopharmaceutical products), but revenue is driven by three distinct streams: Net Product Revenues (~85%), Royalty Revenues (~13%), and Milestone/Contract Revenues (~2%).
- **Key geographies**: Primarily the United States (where it commercialises its own products), with growing direct commercialisation in Europe (Opzelura) and global reach through partnerships (Novartis, Eli Lilly).
- **Business model type**: Asset-light manufacturing (outsourced to third-party contract manufacturing organisations) with extremely high intellectual property value and heavy R&D reinvestment.
- **Competitive position**: A dominant player in myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD) with Jakafi, and a first-mover in topical JAK inhibitors for dermatology (Opzelura).
- **Recent major events**: The 2024 acquisition of exclusive global rights for tafasitamab (Monjuvi), the 2025 launch of Niktimvo for chronic GVHD, and label expansions for Zynyz in squamous cell carcinoma of the anal canal (SCAC).

## Revenue Deep Dive



### Jakafi (ruxolitinib)

- **Segment name**: Net Product Revenues - Jakafi
- **Revenue driver formula**: Total Paid Patients x Average Duration of Therapy x Net Price per Patient
- **Historical growth rate**: 8-11% YoY (FY24: $2.79B, FY25: $3.09B)
- **Key growth levers and headwinds**: Driven by paid demand and label expansions in GVHD and essential thrombocythemia (ET). The primary headwind is the impending patent cliff (LOE expected around 2027/2028), which will trigger generic competition.
- **Pricing dynamics**: High list price with significant gross-to-net (GTN) deductions (Medicare Part D rebates, 340B discounts, copay assistance).
- **Revenue recognition notes**: Recognised upon delivery to specialty pharmacies and wholesalers, net of variable consideration (GTN reserves).
- **Seasonality**: Q1 is typically the weakest quarter due to insurance deductible resets and the Medicare Part D "donut hole," leading to higher copay assistance and lower net pricing.

### Opzelura (ruxolitinib cream)

- **Segment name**: Net Product Revenues - Opzelura
- **Revenue driver formula**: Total Prescriptions (TRx) x Net Price per Tube
- **Historical growth rate**: 30-50% YoY (FY24: $508M, FY25 estimated ~$650M, FY26 Guidance: $750M-$790M)
- **Key growth levers and headwinds**: Driven by patient demand in atopic dermatitis (AD) and vitiligo, plus European expansion. Headwinds include strict payer step-therapy requirements and high channel inventory fluctuations.
- **Pricing dynamics**: Highly sensitive to payer coverage and commercial rebating.
- **Seasonality**: Less pronounced than Jakafi, but Q1 faces similar deductible-driven GTN pressures.

### Other Hematology/Oncology (Niktimvo, Monjuvi, Zynyz, Iclusig, Pemazyre)

- **Segment name**: Net Product Revenues - Other Hematology/Oncology
- **Revenue driver formula**: Patient Volume x Net Price
- **Historical growth rate**: Highly variable due to new launches (Niktimvo generated $152M in its FY25 launch year; Monjuvi grew 21% to $145M in FY25).
- **Key growth levers**: Label expansions into earlier lines of therapy and new geographic approvals.

### Royalty Revenues

- **Segment name**: Royalty Revenues (Jakavi, Olumiant, Tabrecta)
- **Revenue driver formula**: Partner Net Sales x Tiered Royalty Rate %
- **Historical growth rate**: 5-10% YoY
- **Key growth levers**: Novartis's sales of Jakavi outside the US and Eli Lilly's sales of Olumiant.
- **Revenue recognition notes**: Recognised in the same period the partner records the underlying sales, based on estimates if final reports are delayed.

## Cost Structure



### Variable Costs / COGS

- **Line-by-line breakdown**: Third-party manufacturing costs, raw materials (API), packaging, freight, and royalty payments owed to third parties on Incyte's net product sales.
- **Gross margin range**: 92% - 94% (FY25 GAAP COGS was $372.1M on $5.14B total revenue, yielding a ~92.8% gross margin).
- **Key input costs**: Active Pharmaceutical Ingredients (API) and contract manufacturing fees.
- **How COGS scales**: Highly linear with product volume, though product mix (Opzelura vs. Jakafi) slightly alters the margin profile.

### Operating Expenses

- **R&D**: Extremely high, typically 40-45% of total revenue (FY25 GAAP R&D was $2.1B). Covers clinical trial costs, contract research organisation (CRO) fees, upfront licensing payments, and milestone payments to partners. Costs are expensed as incurred unless they have alternative future uses.
- **SG&A**: Typically 25-30% of revenue (FY25 GAAP SG&A was $1.4B). Driven by the commercial sales force for Jakafi and Opzelura, direct-to-consumer (DTC) marketing campaigns, and corporate overhead.
- **Depreciation & Amortisation**: Relatively low as a % of revenue due to outsourced manufacturing, but includes amortisation of acquired intangible assets.
- **Stock-Based Compensation**: Material expense, typically running at 4-6% of revenue, embedded within both R&D and SG&A.
- **Restructuring / one-time charges**: Occasional spikes due to upfront payments for in-licensing deals or acquisitions (e.g., Escient Pharma acquisition).

### Margin Profile

- **Gross margin**: 92-94% (Stable).
- **Operating margin**: 25-30% on a GAAP basis, expanding as revenue scales, though heavily masked by lumpy R&D milestone payments.
- **Net margin**: 15-20%, highly sensitive to the effective tax rate and R&D lumpiness.

## Balance Sheet Structure

- **Total assets**: Approximately $6.5B - $7.5B.
- **Key asset categories**: Cash, cash equivalents, and marketable securities ($3.6B at FY25 year-end); Accounts Receivable; Inventory; Intangible Assets.
- **Goodwill & intangibles**: Represents 10-15% of total assets, stemming from acquisitions of pipeline assets and commercial rights.
- **Working capital profile**:
  - **DSO**: 45-55 days (standard for specialty pharmacy and wholesaler distribution).
  - **DIO**: 90-120 days (pharma companies hold significant API and finished goods to prevent stockouts).
  - **DPO**: 40-60 days.
  - **Net working capital**: Generally positive, driven by large receivables and inventory balances.
- **PP&E**: Minimal (~5-8% of assets), primarily corporate headquarters and lab equipment in Wilmington, Delaware.
- **Right-of-use assets**: Material but not dominant, representing leased office and laboratory space.

## Capital Expenditure & Investment

- **Capex as % of revenue**: 1-3% (Asset-light model).
- **Maintenance vs. growth**: Almost entirely maintenance and minor lab expansions; growth is funded through R&D OPEX, not CAPEX.
- **Capitalised software**: Minimal.
- **M&A pattern**: Bolt-on acquirer and aggressive in-licenser. Incyte frequently pays upfront cash for global or regional rights to early/mid-stage clinical assets.
- **Typical acquisition multiple**: Not applicable on an EBITDA basis; acquisitions are valued on risk-adjusted NPV of the clinical pipeline.

## Debt & Capital Structure

- **Total debt**: Minimal traditional debt. The company operates with a highly net-cash-positive balance sheet.
- **Debt/EBITDA ratio**: ~0.0x (Effectively unlevered).
- **Credit rating**: Not actively rated for major debt issuance due to lack of borrowing.
- **Key debt instruments**: Historically utilised convertible senior notes, but currently relies on its massive cash pile.
- **Share repurchase programme**: Active. The company frequently uses its free cash flow to offset dilution from stock-based compensation and return capital to shareholders.
- **Dividend policy**: No dividend. Capital is entirely allocated to R&D, M&A, and share repurchases.

## Cash Flow Characteristics

- **Operating cash flow conversion**: OCF / Net Income is often >1.5x due to massive non-cash add-backs (SBC, depreciation, and acquired in-process R&D).
- **Free cash flow margin**: 20-25% (FCF / Revenue), highly robust due to low CAPEX requirements.
- **Major non-cash items**: Stock-based compensation, deferred income taxes, and amortisation of intangibles.
- **Working capital cash flow impact**: Receivables growth consumes cash as revenues scale, but this is easily covered by high gross margins.
- **Cash tax rate vs. GAAP effective tax rate**: Cash taxes are often lower than GAAP taxes due to R&D tax credits and the utilisation of historical net operating losses (NOLs) or orphan drug credits.

## Sheet Structure

1. **Assumptions**: Hardcoded drivers for epidemiology, market share, pricing, GTN deductions, and OPEX margins.
2. **Revenue Build - Jakafi**: Patient volume, duration, gross price, GTN %, net revenue.
3. **Revenue Build - Opzelura**: TRx volume, net price per tube, US vs. Ex-US split.
4. **Revenue Build - Other Products**: Line-by-line builds for Niktimvo, Monjuvi, Zynyz, Iclusig, Pemazyre.
5. **Revenue Build - Royalties**: Partner sales projections (Jakavi, Olumiant) x royalty rates.
6. **Pipeline Risk-Adjustment (rNPV)**: Probability of success (PoS) weightings for Phase 2/3 assets (e.g., povorcitinib, mutant CALR).
7. **Consolidated Income Statement**: Total revenues, COGS, R&D, SG&A, operating income, net income, EPS.
8. **Gross-to-Net (GTN) Schedule**: Tracks gross sales, rebates, discounts, and net sales (crucial for pharma).
9. **Balance Sheet**: Cash, AR, Inventory, Intangibles, AP, Accrued Expenses, Equity.
10. **Cash Flow Statement**: OCF, CFI, CFF, ending cash balance.
11. **Working Capital Schedule**: DSO, DIO, DPO calculations.
12. **Depreciation & Amortisation Schedule**: PP&E roll-forward and intangible amortisation.
13. **Shareholders' Equity & Shares**: SBC dilution, share repurchases, basic and diluted share count.
14. **Tax Schedule**: R&D credits, deferred tax assets/liabilities, effective vs. cash tax rate.
15. **DCF Valuation**: Unlevered free cash flow, WACC, terminal value, implied share price.

## Key Financial Relationships

1. `Jakafi Net Revenue = (Total US MPN/GVHD Patients x Market Share %) x Annual List Price x (1 - GTN Deduction %)`
2. `Opzelura Net Revenue = (Total US AD/Vitiligo TRx) x Net Price per Tube + Ex-US Net Revenue`
3. `Total Net Product Revenue = Jakafi Net Revenue + Opzelura Net Revenue + Niktimvo Net Revenue + Monjuvi Net Revenue + Zynyz Net Revenue + Iclusig Net Revenue + Pemazyre Net Revenue`
4. `Jakavi Royalty Revenue = Novartis Ex-US Jakavi Net Sales x Tiered Royalty Rate (approx. 20%)`
5. `Total Revenue = Total Net Product Revenue + Royalty Revenues + Milestone/Contract Revenues`
6. `COGS = Total Net Product Revenue x COGS Margin (historically 7-8%)`
7. `Gross Profit = Total Revenue - COGS`
8. `R&D Expense = Base R&D (historical run-rate growing at inflation) + Upfront/Milestone Payments for New Licenses`
9. `SG&A Expense = Base Corporate Overhead + (Total Net Product Revenue x Variable Selling/Marketing %)`
10. `Operating Income = Gross Profit - R&D Expense - SG&A Expense`
11. `Unlevered Free Cash Flow = Operating Income x (1 - Cash Tax Rate) + D&A + SBC - Capex - Change in Net Working Capital`
12. `Diluted Shares Outstanding = Basic Shares + Dilutive Impact of Options/RSUs - (Share Repurchase $ / Average Share Price)`

## Cross-Sheet Dependencies

- The **Revenue Build** sheets (Jakafi, Opzelura, Other, Royalties) are the critical chain. They feed directly into the top line of the **Consolidated Income Statement**.
- The **Revenue Build** also drives the **Working Capital Schedule** (Accounts Receivable is a function of Total Revenue; Inventory is a function of COGS).
- The **Pipeline Risk-Adjustment** sheet feeds future projected revenues into the out-years of the **Consolidated Income Statement**, which is vital for offsetting the Jakafi LOE in the **DCF Valuation**.
- The **Cash Flow Statement** depends on Net Income from the **Income Statement** and changes in working capital from the **Working Capital Schedule**.
- Circularity risk is minimal due to the lack of debt, but could occur if interest income on the massive cash balance is modelled to feed back into Net Income (Cash -> Interest Income -> Net Income -> Cash). Use a beginning-of-period cash balance for interest income calculations to break the loop.

## Sign Convention

- **Revenues**: Positive.
- **Expenses (COGS, R&D, SG&A, Interest, Taxes)**: Positive in their specific schedules, but subtracted in aggregation formulas (e.g., `Gross Profit = Revenue - COGS`).
- **Assets**: Positive.
- **Liabilities & Equity**: Positive.
- **Cash Flow**: Inflows are positive, outflows (Capex, share repurchases) are negative.

## Things Most Likely to Go Wrong

- **Underestimating the Jakafi LOE Cliff**: Jakafi loses exclusivity around 2027/2028. The model must show a steep, rapid decline in Jakafi revenues (often 80%+ erosion within 2 years of generic entry) rather than a smooth terminal growth rate.
- **Mismodelling Q1 Seasonality**: Incyte experiences severe Q1 revenue dips due to Medicare Part D donut hole dynamics and copay resets. Annualising Q1 results will drastically understate full-year revenue.
- **Lumpy R&D Expenses**: Incyte frequently records massive, one-time GAAP R&D expenses for upfront licensing deals. Projecting R&D as a flat % of revenue based on a year with heavy deal-making will artificially depress out-year margins.
- **Gross-to-Net (GTN) Disconnects**: List price increases rarely drop to the bottom line. The model must assume GTN deductions widen over time as payer pushback increases.
- **Ignoring Ex-US Royalties**: Jakavi (Novartis) and Olumiant (Lilly) royalties are pure-margin revenue. Failing to model these separately from product sales will distort COGS and gross margin calculations.
- **Opzelura Channel Inventory Swings**: Opzelura revenues frequently detach from underlying prescription (TRx) demand due to wholesaler stocking/destocking. The model must rely on patient demand, not just reported shipments.
- **Stock-Based Compensation**: SBC is a massive non-cash add-back. Excluding it from "adjusted" operating margins flatters the company's profitability profile significantly.
- **Constant Currency Adjustments**: European sales of Opzelura and royalties from Novartis are subject to FX swings. The model should note that reported growth may differ from constant-currency growth.

## Validation Checks

- "Gross margin should be in the 92-94% range; flag if outside this band."
- "R&D as a % of revenue should run between 35-45%; flag if it drops below 30% as this implies pipeline starvation."
- "Capex as a % of revenue should not exceed 3% (asset-light model)."
- "Operating cash flow conversion (OCF / Net Income) should be >1.2x due to heavy SBC and D&A add-backs."
- "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period."
- "Jakafi revenue must show a severe negative growth rate (cliff) beginning in 2028."
- "Effective tax rate should be 15-20%; flag if it defaults to the statutory 21% without accounting for orphan drug/R&D credits."
- "Net debt should remain negative (cash > debt) unless a transformational M&A event is manually triggered in the assumptions."

## Key Assumptions (Default Values)

| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Jakafi FY26 Revenue Guidance | 3,245 | $ Millions | Midpoint of management's FY26 guidance ($3.22B - $3.27B) [1] |
| Opzelura FY26 Revenue Guidance | 770 | $ Millions | Midpoint of management's FY26 guidance ($750M - $790M) [1] |
| Total Net Product Rev FY26 Guidance | 4,855 | $ Millions | Midpoint of management's FY26 guidance ($4.77B - $4.94B) [1] |
| Jakafi LOE Year | 2028 | Year | Expected generic entry; triggers steep revenue erosion |
| COGS Margin | 7.5 | % of Revenue | Based on FY25 GAAP COGS of $372M on $5.14B total revenue [1] |
| R&D Margin (Base) | 40.0 | % of Revenue | Based on FY25 GAAP R&D of $2.1B on $5.14B revenue, adjusted for lumpiness [1] |
| SG&A Margin | 27.0 | % of Revenue | Based on FY25 GAAP SG&A of $1.4B on $5.14B revenue [1] |
| Effective Tax Rate | 18.0 | % | Historical average accounting for R&D and orphan drug credits |
| DSO (Days Sales Outstanding) | 50 | Days | Standard specialty pharma collection period |
| DIO (Days Inventory Outstanding) | 100 | Days | Pharma standard for API and finished goods buffering |
| DPO (Days Payable Outstanding) | 45 | Days | Historical average for CRO and manufacturing payables |
| Capex as % of Revenue | 2.0 | % | Asset-light manufacturing model |
| Discount Rate (WACC) | 8.5 | % | Standard biopharma WACC (low debt, high beta) |
| Terminal Growth Rate | -2.0 | % | Negative terminal rate reflects LOE cliffs inherent in pharma models |

## Data Sources & Benchmarks

- **SEC Filings**: Incyte Investor Relations page and SEC EDGAR (10-K, 10-Q, 8-K).
- **Key Peers**: Vertex Pharmaceuticals (VRTX), Regeneron (REGN), BioMarin (BMRN), Alnylam (ALNY), Argenx (ARGX).
- **Industry Data Sources**: IQVIA (for TRx and NRx prescription data), Symphony Health (for weekly script tracking of Opzelura).
- **Consensus Estimates**: Bloomberg, FactSet, or Visible Alpha for pipeline risk-adjustment consensus and out-year Jakafi erosion curves.
- **Clinical Data**: ClinicalTrials.gov for tracking the 14 pivotal trials Incyte currently has underway.

## Sources

- Incyte Corporation Q4 and Full Year 2025 Financial Results Press Release (February 10, 2026)
- Incyte Corporation Q1 2025 Financial Results Press Release
- Incyte Corporation Q4 and Full Year 2024 Financial Results Press Release
- SEC.gov EDGAR Database (INCY filings)

---

## Frequently asked questions

### What does Incyte Corporation do?

Incyte Corporation is a global commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. It primarily operates in the areas of haematology, oncology, and inflammation and autoimmunity.

### How does Incyte generate its revenue?

Incyte's revenue is primarily driven by Net Product Revenues, which constitute approximately 85% of its total revenue. The company also generates significant Royalty Revenues, accounting for about 13%, with Milestone and Contract Revenues making up the remaining 2%.

### What are the key financial assumptions in the Incyte model?

Key financial assumptions in the Incyte model include a revenue growth rate of approximately 14.4% and COGS as a percentage of revenue around 5.7%. Research and Development (R&D) is assumed to be 35% of revenue, while Selling, General, and Administrative (SGA) expenses are modeled at about 25.3% of revenue.

### How does Incyte's asset-light business model impact its capital expenditures?

Incyte operates an asset-light manufacturing model, outsourcing production to third-party organizations. This results in minimal capital expenditures, typically ranging from 1-3% of revenue, primarily for maintenance and minor lab expansions rather than growth-related investments.

### Where can I download a financial model for Incyte?

A comprehensive Excel financial model for Incyte is available for download, designed as an equity valuation and scenario planning tool. This model helps users assess the company's financial performance and strategic outlook.

### What is the primary purpose of the Incyte financial model?

The primary purpose of the Incyte financial model is to provide an equity valuation and scenario planning tool for analysts and portfolio managers. It helps assess Incyte's ability to offset the impending loss of exclusivity for Jakafi through the growth of Opzelura, recent launches, and its clinical pipeline.

[Interactive forecast calculator](https://finamodel.com/companies/incyte/forecast)